Prostacyclin and their analogs, the prostacyclin route, soluble guanylate cyclase modulators, the endothelin pathway, phosphodiesterase-5 inhibitors (PDE5), and inhaled NO are some of the main mechanisms that are targeted by PAH therapeutics [3]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.